Trials / Completed
CompletedNCT05285540
Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia
A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of DT-216 in Adult Patients With Friedreich Ataxia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Design Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DT-216 | DT-216 will be administered by intravenous (IV) injection |
| DRUG | DT-216 matching Placebo | Placebo will be administered by intravenous (IV) injection |
Timeline
- Start date
- 2022-03-11
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
- First posted
- 2022-03-17
- Last updated
- 2023-03-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05285540. Inclusion in this directory is not an endorsement.